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ARTICLE
Disease-associated mutations in Niemann-Pick type
C1 alter ER calcium signaling and neuronal plasticity
Scott A. Tiscione1, Oscar Vivas1, Kenneth S. Ginsburg2, Donald M. Bers2, Daniel S. Ory3, Luis F. Santana1, Rose E. Dixon1, and
Eamonn J. Dickson1
Niemann-Pick type C1 (NPC1) protein is essential for the transport of externally derived cholesterol from lysosomes to other
organelles. Deficiency of NPC1 underlies the progressive NPC1 neurodegenerative disorder. Currently, there are no curative
therapies for this fatal disease. Given the Ca2+ hypothesis of neurodegeneration, which posits that altered Ca2+ dynamics
contribute to neuropathology, we tested if disease mutations in NPC1 alter Ca2+ signaling and neuronal plasticity. We
determine that NPC1 inhibition or disease mutations potentiate store-operated Ca2+ entry (SOCE) due to a presenilin
1 (PSEN1)–dependent reduction in ER Ca2+ levels alongside elevated expression of the molecular SOCE components ORAI1
and STIM1. Associated with this dysfunctional Ca2+ signaling is destabilization of neuronal dendritic spines. Knockdown of
PSEN1 or inhibition of the SREBP pathway restores Ca2+ homeostasis, corrects differential protein expression, reduces
cholesterol accumulation, and rescues spine density. These findings highlight lysosomes as a crucial signaling platform
responsible for tuning ER Ca2+ signaling, SOCE, and synaptic architecture in health and disease.
Introduction
Lysosomes are membrane-bound acidic organelles found in
every eukaryotic cell. Historically known as catabolic sites for
degradation and recycling of waste products, our under-
standing of their functional responsibilities has dramatically
expanded and includes essential roles for nutrient sensing,
transcriptional regulation, metabolic homeostasis, and Ca2+
signaling (Xu and Ren, 2015; Saxton and Sabatini, 2017). Their
dynamic positioning and growing repertoire of cellular
functions have elevated the lysosome from “garbage can” to a
signaling organelle exquisitely positioned to influence cellular
growth and survival. Accumulating evidence suggests that
dysfunction of endolysosomal and autophagic pathways is
associated with the progression of neurodegenerative dis-
eases, such as Alzheimer’s, Parkinson’s, and inherited lyso-
somal storage disorders characterized by the intralysosomal
buildup of partially degraded metabolites (Laplante and
Sabatini, 2012; Fraldi et al., 2016; Castellano et al., 2017). De-
spite the involvement of lysosomes in neurodegenerative
disease progression, the molecular mechanisms that link lyso-
somes to neuronal dysfunction have not been fully established.
A common metabolite that excessively accumulates across
several neurodegenerative disorders is the organic sterol
cholesterol (Liu et al., 2010). A significant portion of cellular
cholesterol is exogenously imported in lipoproteins via
clathrin-mediated endocytosis. As internalized vesicles mature
into late-endosomes/lysosomes, acid lipases free cholesterol
from lipoproteins. Consequently, luminal Niemann-Pick type
C2 (NPC2) proteins deliver cholesterol to membrane-spanning
NPC1 proteins to facilitate cholesterol transport across the late-
endosome/lysosome membrane. Following its transport to the
cytoplasmic leaflet of late-endosome/lysosome membranes,
sterol transfer proteins such as ORP5 and ORPL1 act to transfer
cholesterol to the ER (Du et al., 2011; Zhao and Ridgway, 2017).
Underscoring the importance of NPC1-mediated cholesterol
egress is the fatal neurodegenerative disorder NPC1 disease.
NPC1 disease arises from a loss-of-function mutation in the
NPC1 protein that results in a massive accumulation of cho-
lesterol in lysosomes and significant perturbation of cholesterol
distribution and homeostasis (Millard et al., 2000; Vanier and
Millat, 2003). Despite the correlation between dysfunctional
cholesterol homeostasis and neuronal cell death in NPC1 dis-
ease, the molecular mechanisms that facilitate neurodegeneration
are currently unknown.
The Ca2+ hypothesis of neurodegeneration postulates that
sustained disturbances in Ca2+ signaling are pivotal for the
pathogenesis of various neurodegenerative disorders (Berridge,
2010). Indeed, neuronal Ca2+ signaling plays a fundamental role
in a wide variety of events, including electrical excitability,
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synaptic plasticity, gene transcription, and survival (Berridge,
2010; Brini et al., 2014;Wu et al., 2016; Pchitskaya et al., 2018). In
neurons, the main intracellular source of Ca2+ comes from the
ER. Triggered Ca2+ release from the ER can be accomplished by
hormone or neurotransmitter binding to Gαq-coupled receptors
on the plasmamembrane (PM). Following the release of ER Ca2+,
two major mechanisms serve to refill depleted stores: (1) sarco-
ER calcium ATPases (SERCA) and (2) store-operated Ca2+ entry
(SOCE). Classically, the molecular identity of the proteins
choreographing SOCE are STIM proteins in the ER membrane
and ORAI channels in the PM (Prakriya and Lewis, 2015). Fol-
lowing ER Ca2+ depletion, STIM proteins sense the reduction in
ER luminal Ca2+, subsequently oligomerize, and translocate to
ER–PM contact sites, where they activate Ca2+-conducting ORAI
channels; this results in the flux of extracellular Ca2+ into the
cell, where it is then sequestered into the ER via SERCA. Accu-
mulating evidence suggests that dysregulation of SOCE in neu-
rons perturbs intracellular Ca2+ signaling and contributes to the
pathogenesis of neurodegenerative disorders (Sun et al., 2014;
Wu et al., 2016; Bollimuntha et al., 2017; Secondo et al., 2018).
Given reports that ER Ca2+ pathways are dysregulated across
several neurodegenerative diseases and the correlation between
altered cholesterol homeostasis and neurodegeneration, we hy-
pothesized that the aberrant cholesterol efflux in NPC1 disease
may perturb ER Ca2+ signaling pathways.
Here, we describe a molecular pathway linking cholesterol
egress from lysosomes to the tuning of ER Ca2+ and SOCE, which
influences cytoplasmic Ca2+ concentrations and synaptic plas-
ticity in neurons.
Results
Cholesterol and Ca2+ are misregulated in NPC1I1061T disease
The most common NPC disease mutation, NPC1I1061T, results in
misfolding of the NPC1 protein, its subsequent targeting for
degradation (Gelsthorpe et al., 2008), and thus its functional
loss. Blotting for NPC1 revealed the anticipated 80% reduction in
NPC1 protein from NPC1I1061T patient fibroblasts compared with
healthy patient fibroblasts (Fig. 1 A). The primary characteristic
of NPC disease is the massive accumulation of cholesterol in
lysosomes. To confirm this cellular phenotype, we stained for
unesterified cholesterol using the naturally fluorescent filipin
compound. Fig. 1 B shows representative superresolution images
of filipin-stained healthy and NPC1I1061T fibroblasts; qualita-
tively, the black vesicular structures represent cholesterol un-
able to exit lysosomes. These data show that the lysosomal NPC1
protein and, as a consequence, lysosomal cholesterol homeostasis
are significantly perturbed in NPC1I1061T disease fibroblasts.
Next, we tested the hypothesis that Ca2+ dynamics are mis-
regulated in NPC1I1061T disease fibroblasts. To this end, healthy
and NPC1I1061T fibroblasts were loaded with cytosolic Ca2+ indi-
cator Fluo-4 and subjected to a protocol with the SERCA inhib-
itor thapsigargin (TG) in an external 0 mM Ca2+ solution,
followed by a 2 mM Ca2+-containing solution. This experimental
protocol allows us to analyze the Ca2+ released from the ER (as
the area under the curve [AUC] between 150 s and 450 s) and
SOCE (AUC >450 s). We found that NPC1I1061T fibroblasts have
significantly altered Ca2+ dynamics (Fig. 1 C). Quantitative
analyses determined NPC1I1061T fibroblasts have enhanced
Ca2+ influx, less Ca2+ release from the ER, and larger, more
rapid SOCE following TG treatment (Fig. 1, D and E). The
consequences of these alterations in Ca2+ dynamics are ele-
vated resting cytoplasmic Ca2+ levels, as indicated by a sig-
nificant increase in Fluo-4 intensity (Fig. 1 F) and Fura-2 ratios
(Fig. 1 G). Calibration of these cytosolic Ca2+ dyes revealed that
NPC1I1061T fibroblasts have significantly increased cytoplas-
mic Ca2+ concentrations (healthy, 153 nM ± 10 nM; NPC1I1061T,
230 nM ± 7 nM; n = 6). To fully underscore that these alter-
ations in Ca2+ signaling were due to NPC1 dysfunction and not
to adaptation of this patient cell, we measured Ca2+ dynamics
under four additional conditions of NPC1 dysfunction: two
additional NPC1 disease patient cell lines (NPC1I1061T/I1061T and
NPC1I1061T/P1007A), NPC1−/− cells, and mouse embryonic fi-
broblasts (MEFs) treated overnight with an inhibitor of NPC1
(U18666A [UA]; 1 µM; Lu et al., 2015). Across each experi-
mental condition, TG-mediated Ca2+ release was reduced and
SOCE was elevated (Fig. S1). Collectively, these data show
lysosomal cholesterol is associated with altered Ca2+ dynamics
in NPC1 disease and support the hypothesis that NPC1-
mediated cholesterol efflux tunes Ca2+ homeostasis.
NPC1I1061T fibroblasts have greater endogenous ORAI-STIM
Ca2+ influx
To determine the molecular identity of the enhanced Ca2+
influx into NPC1I1061T cells, we transfected cells with a ge-
netically encoded Ca2+ sensor targeted to the PM (GCaMP-
CAAX; Fig. 2, A and B) and studied the effects of pharmaco-
logical blockade of candidate channels. Fig. 2, A and B, shows
representative confocal images of healthy and NPC1I1061T pa-
tient fibroblasts transfected with GCaMP-CAAX, focused at
the PM footprint. Measurement of the resting PM intensity
revealed a 2.6-fold (±0.7) higher intensity of NPC1I1061T fi-
broblasts, suggesting greater Ca2+ influx across the PM. To
test if STIM–ORAI interactions represent the molecular
identity of this differential Ca2+ flux, we treated cells with an
inhibitor of ORAI1 channels, AnCoA4 (Sadaghiani et al., 2014).
Measurement of GCaMP-CAAX fluorescent intensities at the
PM revealed a significantly greater AnCoA4-sensitive com-
ponent from NPC1I1061T fibroblasts (healthy, 49% reduction
±6.7%; NPC1I1061T, 75% reduction ±3.5%; Fig. 2 C). Patch-clamp
electrophysiology recordings confirmed a larger AnCoA4-
sensitive calcium release–activated channel current (ICRAC)
conductance from NPC1I1061T fibroblasts (Fig. S2 A) and suggests
enhanced resting ORAI1 conductance in NPC1 disease cells.
To determine if enhanced abundance or altered ORAI1 and
STIM1 distribution contributes to increased ORAI1-dependent
Ca2+ conductance in NPC1I1061T disease we performed Western
blot analysis and superresolution nanoscopy. Western blot
analysis revealed significant increases in total protein levels of
ORAI1 (33% ± 11%) and STIM1 (20% ± 4%) from NPC1I1061T fi-
broblasts relative to healthy patient cells (Fig. 2, D and E), while
STIM2 protein expression was not significantly altered (Fig. S2
C). Next, using superresolution total internal reflection fluo-
rescence (TIRF) microscopy, we generated localization maps of
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endogenous ORAI1 and STIM1 proteins to determine if increased
protein levels correlated to altered size and distribution of
puncta. Fig. 2 F shows representative TIRF and superresolution
TIRF images of immunolabeled ORAI1 in healthy and NPC1I1061T
fibroblasts. Quantitative analyses of superresolution localization
maps revealed the abundance and average size of ORAI1 puncta
are increased (Figs. 2 G and S2 D) in NPC1I1061T fibroblasts. For
STIM1 (Fig. 2 H), we also found a similar trend of increased a-
bundance (Fig. 2 I) and average size (Figs. 2 I and S2 D) of puncta
from NPC1I1061T TIRF localization maps. Collectively, these data
support the interpretation that Ca2+ influx via ORAI1 is higher in
NPC1I1061T patient cells, with multiple assays providing evidence
that altered STIM1/ORAI1 protein abundance and distribution
contribute to this increase.
NPC1I10161T patient cells have increased size and number of
resting STIM1 and ORAI1 puncta
Given the enhanced Ca2+ influx (Fig. 2, A–C; and Fig. S2 A) and
increased STIM1 and ORAI protein levels/distribution (Fig. 2,
D–I) in NPC1I1061T fibroblasts, we wanted to determine if the
number of interactions between STIM1 and ORAI1 puncta at rest
were also increased. To this end, we used superresolution mi-
croscopy to measure the degree of colocalization between en-
dogenous STIM1 and ORAI1 in healthy and NPC1 patient
fibroblasts. Superresolution images revealed that the degree of
overlapping pixels between ORAI1 and STIM1 was significantly
elevated in NPC1I1061T fibroblasts relative to healthy cells (com-
pare Fig. 3, A and B). Quantitative analysis of superresolution
images revealed an approximately threefold increase in the
percentage of overlapping pixels, with both STIM1/ORAI1
puncta area and density significantly increased (Fig. 3 C). Next, we
investigated whether STIM1/ORAI1 puncta formation occurred
more rapidly in NPC1I1061T fibroblasts. To this end, we expressed
mCherry-STIM1 and Orai1-EGFP and monitored their dynamics
before and during TG application. Fig. S2 F shows representative
images of resting healthy and NPC1I1061T fibroblasts transfected
with ORAI1-GFP and mCherry-STIM1. As expected, NPC1I1061T fi-
broblasts displayed larger and more abundant STIM1/ORAI1
puncta in resting cells. Depletion of ER Ca2+ stores with a 5-min
application of TG revealed an acceleration in STIM1/ORAI1 puncta
formation in NPC1I1061T fibroblasts (Fig. S2, G and H), which also
appeared to be larger than their healthy cell counterparts (Fig. S2
I). These data suggest that STIM1 and ORAI1 are not only pre-
associated in resting NPC1I1061T fibroblasts but also may form
puncta more quickly following depletion of intracellular Ca2+
stores.
ER Ca2+ is reduced in NPC1I1061T fibroblasts
Having established that SOCE and STIM1/ORAI1 clustering are
enhanced in NPC1I1061T fibroblasts, we next tested if this occurs
as a consequence of reduced ER luminal Ca2+ levels (Fig. 4 A). A
reduction in ER Ca2+ levels would decrease the free Ca2+ con-
centration available to bind STIM1’s EF-hand domain and con-
sequently increase the likelihood of STIM1 activation. To
measure ER Ca2+, healthy and NPC1I1061T patient fibroblasts were
transfected with D1-ER (Palmer et al., 2004), a genetically en-
coded Ca2+ sensor targeted to the lumen of the ER. Ca2+ binding
to the probe increases Fo¨rster resonance energy transfer (FRET)
between CFP and YFP fluorophores to increase the FRET ratio
(Fig. 4 B). Fig. 4 C shows representative images of FRET ratios in
Figure 1. NPC1 disease fibroblasts have altered cholesterol homeostasis and Ca2+ signaling. (A) Left: Representative Western blot of NPC1 in healthy
and NPC1I1061T disease fibroblasts. Right: Quantification of NPC1 protein expression, normalized to β-actin. (B) Representative superresolution images of
healthy and NPC1I1061T fibroblasts fixed and stained with filipin to show cholesterol distribution. Scale bar of inset represents 2.5 µm. (C) Representative time
series from Fluo-4–loaded healthy and NPC1I1061T fibroblasts. (D–F)Quantification of Fluo-4 signals from healthy and NPC1I1061T fibroblasts. (G) Comparison of
resting fura-2 ratios. Error bars represent the standard error of the mean.
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Figure 2. Resting SOCE, coupled with STIM1/ORAI1 expression and distribution, is increased in NPC1I1061T fibroblasts. (A) Diagram of SOCE in healthy
cells (i), schematic of GCAMP-CAAX Ca2+ probe in healthy cells (ii), and representative live confocal images of a healthy cell expressing GCAMP-CAAX (iii).
(B) Same as A, only for NPC1I1061T fibroblasts. (C) Quantification of resting GCAMP-CAAX fluorescence. Gray portion indicates the AnCoA4-sensitive reduction
in resting fluorescence. (D) Left: Representative ORAI1 Western blot from healthy and NPC1I1061T fibroblasts. Right: Quantification of ORAI1 protein expression
in fibroblasts, normalized to β-actin. (E) Same as D, only for STIM1. (F) Top: Representative TIRF images from healthy and NPC1I1061T fibroblasts stained for
anti-ORAI1. Bottom: Superresolution localization map from dashed boxes within the TIRF images; dashed lines delineate edges of cells. Inset: Representative
ORAI1 puncta. Scale bar represents 0.25 µm. (G) Quantification of anti-ORAI1 localization map. (H and I) Same as F and G, only for STIM1. Error bars represent
the standard error of the mean.
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resting healthy and NPC1I1061T fibroblasts transfected with this
probe. Quantification of cells expressing the probe revealed a
significant reduction in FRET ratio of ∼25% in NPC1I1061T fi-
broblasts (Fig. 4 D), suggesting reduced ER Ca2+ levels. Calibra-
tion of the D1-ER FRET probe revealed healthy cells as having
a luminal ER free Ca2+ concentration of ∼270 µM (healthy,
268 µM ± 15 µM; n = 5), while NPC1I1061T cells at a significantly
lower ER Ca2+ concentration of ∼170 µM (NPC1I1061T 167 µM ±
26 µM; n = 6). To confirm this observation, we measured the
total Ca2+ released from intracellular stores following applica-
tion of the Ca2+ ionophore ionomycin (in the absence of extra-
cellular Ca2+). Experiments from Fluo-4–loaded cells treated
Figure 3. Size and number of STIM1/ORAI1 puncta are en-
hanced in NPC1I1061T fibroblasts. (A) Left: Representative
superresolution image of a healthy fibroblast immunostained for
ORAI1 (red), STIM1 (green), and merged (yellow). Right: Binary
colocalization map of overlapping pixels from ORAI1 and STIM1
channels. Bottom: Zoomed regions denoted by dashed boxes
and representative line plots taken from each solid white line.
(B) Same as A, only for an NPC1I1061T fibroblast. (C) Quantifi-
cation of superresolution images. Error bars represent the
standard error of the mean.
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with ionomycin (2.5 µM) revealed a significant reduction in the
pool of Ca2+ mobilized to the cytoplasm in NPC1I1061T fibroblasts
(Fig. 4, E–G). Together, these experiments strongly suggest ER
luminal Ca2+ concentrations are reduced in NPC disease.
Next, we wanted to determine if the reduction of ER luminal
Ca2+ from NPC1I1061T fibroblasts was due to transcriptional
changes in protein expression. ER luminal Ca2+ concentration is
controlled by threemain parameters: (1) Ca2+ buffering proteins,
(2) Ca2+ reuptake pumps, and (3) rate of intrinsic Ca2+ leak. We
hypothesized that loss of NPC1 function may alter the protein
levels underlying one or more of these parameters. To test this
hypothesis, we performed Western blots for several proteins
that may alter ER Ca2+ load. We began with SERCA, the ER’s
primary pathway of refilling and maintenance of luminal Ca2+.
Western analysis of SERCA isoforms 2A/2B revealed a signifi-
cant increase of 29% ± 9% in NPC1I1061T fibroblasts (Fig. 4 H),
making it unlikely to be directly involved in regulating the en-
hanced SOCE in NPC disease. Next, we tested Calreticulin, an
important luminal ER Ca2+ buffering protein, and found it not
significantly altered at the protein level in NPC1I1061T fibroblasts
(Fig. 4 I). Finally, we tested the hypothesis that NPC1I1061T fi-
broblasts have a leakier ER compared with healthy patient cells
Figure 4. Resting luminal ER Ca2+ is reduced in NPC1I1061T fibroblasts. (A) Graphical depiction of differential ER Ca2+, mediated by enhanced ER Ca2+
leak in NPC1I1061T fibroblasts. (B) Schematic of D1-ER Ca2+ probe. (C) Representative live confocal images of healthy and NPC1I1061T fibroblasts ex-
pressing D1-ER. (D) Quantification of D1-ER FRET ratios. (E) Normalized individual Fluo-4 intensities (gray) and averaged intensity (black, n = 31) from
healthy fibroblasts following addition of a Ca2+-free ionomycin-containing external solution. (F) Same as E, only NPC1I1061T fibroblasts (red, n = 14).
(G) Quantification of the normalized area under the ionomycin curve. (H) Left: Representative Western blot for SERCA 2A/2B from healthy and
NPC1I1061T lysates. Right: Quantification of protein expression, normalized to β-actin. (I) Same as H, only for calreticulin (CALR). (J) Normalized D1-ER
FRET ratios from healthy (black circles) and NPC1I1061T fibroblasts (red squares) following application of TG. Fitted lines (healthy: black; NPC1I1061T: red)
represent one-phase decay curves. (K and L) Quantitative comparison of the slope decay and time constant from the healthy and NPC1I1061T nonlinear
regression curves. Error bars represent the standard error of the mean.
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(see hypothesis; Fig. 4 A). To measure the rate of intrinsic Ca2+
leak from the ER, healthy and NPC1I1061T fibroblasts were
transfected with the D1-ER FRET probe and treated with the
SERCA pump inhibitor TG (500 nM) in the absence of extra-
cellular Ca2+. Decreases in FRET ratio following inhibition of the
SERCA pump represent Ca2+ leaking from the ER (Fig. 4 J). Fit-
ting healthy and NPC1 FRET ratios with one-phase decay re-
gression curves revealed that NPC1I1061T fibroblasts have a
significantly faster time constant of decay (Fig. 4, K and L).
Collectively, these data suggest that NPC1I1061T fibroblasts have a
greater intrinsic ER Ca2+ leak, explaining why their ER free Ca2+
concentration is significantly lower than healthy cells.
Presenilin 1 (PSEN1) mediates the decrease in ER Ca2+ and
enhanced SOCE in NPC1 disease
PSEN1 is one of the core proteins of the γ-secretase complex that
has been suggested to potentiate ER Ca2+ channels (Leissring
et al., 1999) and represent the molecular identity of the low-
conductance ER-leak channels (Nelson et al., 2011; Supnet and
Bezprozvanny, 2011). PSEN1 undergoes endoproteolytic pro-
cessing to produce two fragments, an ∼30-kD N-terminal frag-
ment and ∼20-kD C-terminal fragment. Western blot analysis
revealed that both fragments are significantly elevated in
NPC1I1061T fibroblasts (Fig. 5, A and B). Despite this elevation in
fragments, it is reported that the full-length (∼50 kD) PSEN1
holoprotein functions as the Ca2+ leak channel (Tu et al., 2006).
Due to its low abundance and short half-life (Ratovitski et al.,
1997), we, like others (Walter et al., 1996; Citron et al., 1997;
Ratovitski et al., 1997), failed to detect a holoprotein band in
patient fibroblasts. To overcome this limitation, we overex-
pressed the full-length PSEN1 protein and found that inhibiting
NPC1 cholesterol efflux overnight, with UA, significantly in-
creased PSEN1 holoprotein levels (Fig. 5 C).
An increase in PSEN1 expression and/or activity is predicted
to result in a leakier ER, which may account for the observed
decrease in resting ER Ca2+ levels in NPC1 disease and contribute
to enhanced STIM/ORAI aggregation and SOCE. To test whether
up-regulation of PSEN1 is responsible for these altered Ca2+
phenotypes in NPC disease, we knocked down PSEN1 in
NPC1I1061T fibroblasts and measured ER Ca2+ levels and SOCE
(Fig. 5, D–H). 48-h transfection with siRNA directed against
PSEN1 significantly increased the ionomycin- (Fig. 5, D and E)
and TG-mediated (Fig. 5, F and G) elevations in Ca2+ from NPC
fibroblasts compared with NPC fibroblasts transfected with a
negative nontargeting control. Additionally, the SOCE AUC was
significantly reduced in the PSEN1 knockdown fibroblasts
compared with controls (Fig. 5, F and H). Further evidence of
PSEN1’s ability to influence ER Ca2+ levels is found in Fig. S3,
where we show that treating healthy cells with PSEN1 siRNA
increases ER Ca2+ (Fig. S3, A–C), overexpression of the catalyt-
ically inactive PSEN1D257A (accumulates holoprotein form) de-
creases ER Ca2+ levels and increases the rate of Ca2+ leak from
the ER (Fig. S3, D–F), and PSEN−/− cells have increased TG-
mediated Ca2+ release (Fig. S3, G–I). These data align with
PSEN1’s putative role as an ER Ca2+ leak channel. As a final piece
of evidence that PSEN1 mediates the reduction in ER Ca2+ found
inNPC1 disease, treating PSEN−/− cells with UA did not alter Ca2+
dynamics (Fig. S3, J–O). These findings suggest that changes in
the expression of PSEN1 influence ER Ca2+ concentrations and
contribute to reduced ER Ca2+ levels in NPC1 disease.
Pharmacological elevations in ER Ca2+ have been shown to
adapt NPC1 proteostasis, increase the functional amount of
NPC1 in lysosomal membranes, and rescue the aberrant
storage of cholesterol (Yu et al., 2012). With this in mind, we
tested the hypothesis that treating NPC1I1061T fibroblasts with
PSEN1 siRNA to increase ER Ca2+ levels (Fig. 5, D–G) may in-
crease the amount of NPC1 protein and alter cholesterol
storage. Western blot analysis revealed that 24-h PSEN1
siRNA treatment of NPC1II061T cells increased NPC1 protein
approximately threefold (Fig. 5 I, J) and caused a corre-
sponding decrease in the area and intensity of filipin-positive
vesicles (Fig. 5, K–N). These results demonstrate that in-
creases in PSEN1, which decrease ER Ca2+ levels, may com-
pound cholesterol accumulation in NPC1 disease.
Inhibition of SREBP rescues the Ca2+ and transcriptional
changes of NPC1I1061T fibroblasts
Having established that PSEN1 may be part of the mechanism
linking lysosomal cholesterol dysfunction to alterations in Ca2+
homeostasis in NPC disease, we next tested the hypothesis that
activation of SREBP (sterol-response element–binding protein)
is responsible for the enhanced expression of key Ca2+ handling
proteins, including PSEN1, in NPC1 disease (Fig. 6 A). SREBPs are
transcription factors that govern cellular lipogenesis and cho-
lesterol metabolism. Inactive SREBP (p-SREBP) is associated
with SREBP cleavage-activating protein (SCAP) and an INSIG
family protein, which retains SREBP in the ER membrane in a
cholesterol-dependent manner. When cholesterol content at the
ER falls below a certain threshold (∼5 mol%; Infante and
Radhakrishnan, 2017), such as in NPC1 disease, the SREBP–
SCAP complex dissociates from INSIG and translocates to the
Golgi, where S1P and S2P proteases cleave the SREBP precursor
and release the mature, active form of SREBP (n-SREBP), which
subsequently translocates to the nucleus to up-regulate gene
transcription. Western blot analysis revealed that n-SREBP
(active form) was twofold higher in NPC1I1061T fibroblasts rela-
tive to healthy patient fibroblasts (Fig. 6, B and C). To determine
if SREBP impacts the transcription and translation of Ca2+
handling proteins, we incubated NPC1I1061T fibroblasts with
500 nM PF-429242, an inhibitor of S1P that prevents activation
of SREBP (Fig. 6, B and C), for 24 h alongside vehicle controls and
measured mRNA and protein levels, respectively. qPCR analysis
of mRNA levels revealed PSEN1, STIM1, and ORAI1 are all ele-
vated in NPC1 fibroblasts, with SREBP inhibition decreasing
levels back to healthy levels (Fig. S4, A and B). Analysis of
Western blots revealed that inhibition of SREBP also signifi-
cantly reduced protein levels of SERCA, STIM1, ORAI1, and
PSEN1 (Fig. 6, D and E). These results support the hypothesis
that the SREBP pathway mediates transcriptional changes in
Ca2+ signaling proteins in NPC1 disease.
Given the involvement of the SREBP pathway in influencing
the expression of key Ca2+ signaling proteins in NPC1 disease, we
tested if inhibition of SREBP and subsequent rescue of Ca2+
signaling protein levels restored Ca2+ dynamics. Consistent with
Tiscione et al. Journal of Cell Biology 4147
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this hypothesis, inhibition of NPC1 in SCAP−/− cells, which
lacks the ability to activate the SREBP pathway (Rawson et al.,
1999), failed to alter Ca2+dynamics (Fig. S4, C–E), while treat-
ment of NPC1I1061T fibroblasts with PF-429242 significantly in-
creased the ionomycin-mediated elevation in cytoplasmic Ca2+
(Fig. 6, F and G), the TG-sensitive AUC (Fig. 6 H and I), the
SOCE AUC (Fig. 6 J), and the SOCE/TG ratio (Fig. 6 K) back to
healthy control levels. Appropriate control experiments de-
tailing the effect of PF-429242 on healthy fibroblasts are found
in Fig. S5, A–I.
Figure 5. Differential expression of PSEN1 alters ER Ca2+ and SOCE in NPC1I1061T fibroblasts. (A) Representative PSEN1-NTF and PSEN1-CTF Western
blots from healthy and NPC1I1061T cells with or without siRNA targeting PSEN1. (B) Quantification of differential protein expression, normalized to β-actin.
(C) Top: Representative PSEN1 Western blot from tsA-201 cells transfected with PSEN1 and treated with NPC1 inhibitor, UA, or vehicle control. Bottom:
Quantification of differential PSEN1 protein expression, normalized to β-actin. (D) Averaged intracellular Fluo-4 responses following ionomycin treatment in
NPC1I1061T fibroblasts transfected for 48 h with either negative control siRNA (red) or siRNA targeting PSEN1 (orange). (E) Quantification of AUC, from
NPC1I1061T fibroblasts transfected with PSEN1 (orange) or control (red) siRNA. (F) Averaged time-course of NPC1I1061T fibroblasts transfected with control
siRNA (red) or siRNA targeting PSEN1 (orange). (G)Quantification of the AUC during TG. (H)Quantification of the AUC during SOCE. (I) RepresentativeWestern
blot of NPC1 in healthy and NPC1I1061T fibroblasts with or without siRNA (24 h) targeting PSEN1. (J)Quantification of differential protein expression, normalized
to β-actin. (K) Representative superresolution images of filipin staining from NPC1I1061T fibroblasts treated with control or PSEN1 siRNA for 72 h.
(L–N) Quantification of superresolution filipin images. Error bars represent the standard error of the mean.
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Inhibition of NPC1 alters lysosomal Ca2+ and pH homeostasis
via the SREBP pathway
Until now, we have provided evidence that inhibiting NPC1-
cholesterol transport from lysosome membranes to ER mem-
branes can misregulate ER Ca2+ signaling via the SREBP
pathway. Next, we asked if NPC1 dysfunction influences the
ability of the lysosome itself to release Ca2+ and maintain pH,
two key functions that influence lysosome ability to participate
in signaling cascades. To measure lysosomal Ca2+ release we
overexpressed a genetically encoded Ca2+ indicator targeted to
lysosomal membranes (GCaMP3-ML1; Fig. 7 A; Shen et al., 2012).
Treatment of cells expressing GCaMP3-ML1 with the lysosomal
TRPML agonist ML-SA1 (10 µM) caused a rapid release of Ca2+
from the lysosome lumen into the cytoplasm (Fig. 7 B). Cells
Figure 6. SREBP-mediated control of PSEN1 and
Ca2+ proteins tunes ER Ca2+ and SOCE in NPC1I1061T
fibroblasts. (A) Proposed pathway for SREBP-
mediated alterations of Ca2+ in NPC1 disease. Red
arrows represent proteins/Ca2+ pathways increasing
in NPC1 disease. Blue arrows represent changes fol-
lowing treatment with PF-429242. (B) Representative
inactive SREBP (p-SREBP) and active SREBP (n-SREBP)
Western blots from healthy fibroblasts, NPC1I1061T fibro-
blasts, and NPC1I1061T fibroblasts treated with SREBP
inhibitor, PF-429242. (C) Quantification of differential
protein expression, normalized to β-actin (*, P < 0.5;
**, P < 0.1; ***, P < 0.0001). (D) Left: Representative
Western blots showing SERCA, STIM1, ORAI1, and
PSEN1-CTF protein in healthy fibroblasts and NPC1I1061T
fibroblasts, with or without 24-h pretreatment with PF-
429242. (E) Quantification of the differential protein ex-
pression, normalized to β-actin (*, P < 0.5; **, P < 0.1;
***, P < 0.0001). (F) Normalized Fluo-4 intensity of in-
dividual (gray) and averaged (red/blue) time courses from
NPC1I1061T fibroblasts (red, n = 14) and NPC1I1061T fibro-
blasts (blue, n = 12) treated with the same experimental
protocol as A. (G) Quantification of the AUC during ion-
omycin. (H) Normalized Fluo-4 time series of healthy fi-
broblasts (black), NPC1I1061T fibroblasts (red), NPC1I1061T
fibroblasts (red), and NPC1I1061T fibroblasts treated with
PF-429242 for 24 h (blue). (I) Quantification of the AUC
during TG. (J) Quantification of the AUC during SOCE.
(K) Comparative ratios of the SOCE to TG areas under the
curve. Error bars represent the standard error of the mean.
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incubated overnight with UA (1 µM) to block NPC1-mediated
cholesterol efflux had significantly lower Ca2+ release (Fig. 7, B
and C). This data aligns well with other groups that report re-
duced lysosomal Ca2+ release in NPC1 disease (Lloyd-Evans et al.,
2008; Shen et al., 2012). To determine if the ability of lysosomes
to regulate pH is also compromised after inhibition of NPC1, we
took an optogenetic approach by overexpressing a genetically
encoded, light-activated proton pump targeted to lysosomes
(lyso-pHoenix; Fig. 7 D; Rost et al., 2015). Upon activation with
red light, Arch3 pumps protons into the lysosome lumen to
protonate a pH-sensitive GFP (pHluorin), thereby sensitizing its
emission. Subsequent removal of red light allows endogenous
homeostatic mechanisms (e.g., proton leak) to restore lysosome
pHwithin a few seconds (Fig. 7 E). Treating cells with UA (1 µM)
overnight significantly slowed the deprotonation of pHluorin
(Fig. 7, E–G), suggesting a reduced proton leak. Critically, co-
treatment with a SREBP inhibitor rescued both lysosomal Ca2+
release (Fig. 7, B and C) and lysosomal pH homeostasis (Fig. 7,
E–G), further underscoring the significant role NPC1-mediated
cholesterol–SREBP interactions play in tuning organelle func-
tion. Appropriate control experiments detailing the effect of PF-
429242 treatment alone are found in Fig. S5, J–M.
Inhibition of NPC1 recapitulates the Ca2+ phenotypes of
NPC1I1061T fibroblasts in primary hippocampal neurons
As noted earlier, patients with a NPC1I1061T mutation develop
NPC1 neurodegenerative disease, raising two questions: is the
mechanism described herein conserved in neurons and, if so,
what are the implications of altered neuronal SOCE for NPC
disease? To begin addressing these questions, we treated cul-
tured hippocampal neurons with UA to recapitulate the cellular
cholesterol phenotype of NPC disease (Fig. 8 A) and measured
neuronal Ca2+ signals at dendritic spines (Fig. 8 B). Reminiscent
of NPC1I1061T fibroblasts, UA-dependent accumulations in neu-
ronal lysosome cholesterol resulted in a parallel decrease in ER
Ca2+ levels (Fig. 8 C), increased SOCE (Fig. 8, D and E), and in-
creased resting cytoplasmic Ca2+ concentrations (Fig. 8 F).
In neurons, ER Ca2+ release and STIM- and ORAI-mediated
SOCE reportedly play important roles in the formation and
maturation of dendritic spines (Korkotian et al., 2017). Indeed,
enhanced SOCE has been shown to mediate dendritic spine loss
in an Alzheimer’s model of neurodegeneration (Zhang et al.,
2015). Thus, we wanted to test if inhibition or disease muta-
tions in NPC1 alter dendritic spine density. To do so, cultured
hippocampal neurons (day in vitro [DIV] 21) were fixed and
immunostained for the neuronal marker MAP-2 (blue) and
dendritic spine marker PSD-95 (green). Fig. 7 G shows repre-
sentative images of neurons treated for 24, 48, 72, or 96 h with
1 µM UA or vehicle control (time 0). Quantification of images
revealed that 24-h UA treatment significantly increased the
density of dendritic spines by 48% compared with vehicle-only
controls (Fig. 7 G). This initial increase in spine density is likely
driven by SOCE, as it could be recapitulated by 24-h TG treat-
ment (yellow panel, Fig. 8 G) and antagonized by blocking ORAI1
channels (purple panel, Fig. 8 G). Prolonged 48- to 96-h incu-
bation with UA led to a progressive, time-dependent decrease in
Figure 7. Inhibition of SREBP rescues lysosomal
function following inhibition of NPC1-choelsterol
transport. (A) Schematic of GCaMP3-ML1. (B) Repre-
sentative, normalized changes in GCAMP3-ML1 intensity
from tsA201 cells treated with a vehicle control (black,
n = 9), UA (red, n = 10), or both UA and PF-429242 (blue,
n = 8). (C) Quantification of the AUC following addition
of ML-SA1. (D) Schematic of lyso-pHoenix. (E) Repre-
sentative, normalized changes in lyso-pHoenix intensity
from tsA201 cells treated with a vehicle control (black),
UA (red), or both UA and PF-429242 (blue). (F) One-
phase association curves fitted to the average fluores-
cence recovery of pHoenix following photoactivation.
(G) Quantitative comparison of the slope constants (K
value) from nonlinear regression curves. Error bars
represent the standard error of the mean.
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spine density (48 h, 66% decrease; 72 h, 60% decrease; 96 h, 69%
decrease), which could be rescued by SREBP inhibition (PF-
429242; 96 h, 23% increase). We hypothesize that the time-
dependent decreases in synaptic spine density between 48-h
and 96-h UA treatment is likely an abrupt manifestation of the
disease phenotype that likely happens over the course of years in
patients. To test this supposition, we fixed and Golgi-stained
brain slices from a NPC1I0611T murine animal model that faith-
fully recapitulates patient phenotypes (Praggastis et al., 2015).
Analysis of cerebellar Purkinje neurons, the class of cells most
susceptible to cell death in NPC1 disease, revealed a significant
decrease in spine density between WT and sex-/aged-matched
NPC1I1061T littermates (WT: n = 2, n = 12; I1061T: n = 2, n = 17;
Fig. 8, H and I). These data support a molecular link between
NPC1-mediated egress of cholesterol from lysosomes and Ca2+-
dependent modification of dendritic spine density, which may
underlie the disease progression and neurological symptoms
observed in NPC disease.
Discussion
Mechanisms that link cholesterol metabolism to regulation of
cellular Ca2+ homeostasis remain poorly defined despite their
disruptions being strongly correlated with the development and
progression of pathophysiological conditions (Liu et al., 2010;
Vance, 2012). Here, we show that the lysosomal cholesterol
Figure 8. Inhibition of NPC1 and SREBP pathway
recapitulates NPC1I1061T disease phenotype in pri-
mary neurons and decreases dendritic spine density.
(A) Representative superresolution Airyscan images of
hippocampal neurons treated with vehicle or NPC1 in-
hibitor, UA, for 24 h and then fixed and stained with
filipin. (B) Representative live confocal image of hippo-
campal neurons loaded with Fluo-4; arrows indicate
examples of dendritic spines. (C) Quantification of nor-
malized D1-ER FRET ratio from vehicle-treated and
UA-treated (24 h) hippocampal neurons at rest.
(D) Normalized Fluo-4 SOCE traces from dendritic
spines in hippocampal neurons vehicle treated (black,
n = 14) or UA treated for 24 h (red, n = 11). (E) Quan-
tification of the AUC for the SOCE portion of the time
course. (F) Comparison of standardized resting Fluo-4
intensity from vehicle-treated and UA-treated (24 h)
hippocampal neurons at rest. (G) Left: Representative
images of hippocampal neurons fixed and im-
munostained for MAP-2 (blue) and PSD-95 (green) at
time points of 0-, 24-, 48-, 72-, and 96-h treatment with
UA, 96-h treatment with UA and PF-429242, 24-h
treatment with TG, and 24-h treatment with UA and
AnCoA4. Right: Quantification of dendritic spine density
(number per micrometer), normalized to vehicle control
density; asterisk denotes statistical significance. (H) Left:
Representative images of Golgi-stained Purkinje neurons
from WT mice and NPC1I1061T mice. Middle: Binary
skeleton overlaid each respective representative image.
Right: Zoom from dashed box region of interest; arrows
indicate examples of spines from the generated skeleton.
(I) Quantification of dendritic spine density (number per
micrometer), normalized to WT density. Error bars rep-
resent the standard error of the mean.
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transporter NPC1 has the ability to alter Ca2+ homeostasis and
SOCE in patient fibroblasts and primary hippocampal neurons.
We have found that the NPC1I1061T mutation, which reduces
cholesterol efflux from lysosomes and results in the most
prevalent form of the neurodegenerative NPC1 disease, leads to
(1) differential expression of key Ca2+ signaling and SOCE reg-
ulating proteins, (2) a reduction in luminal ER Ca2+, (3) an in-
crease in resting STIM1–ORAI1 interactions, and (4) enhanced
SOCE, leading to (5) increased cytoplasmic Ca2+ concentrations.
Importantly, we also report that inhibition of NPC1 results in a
decrease in neuronal spine density. Our experimental evidence
suggests that these changes are mediated through the SREBP
pathway. This hypothesis is supported by data showing that
SREBP pathway inhibition normalizes mRNA and protein ex-
pression profiles back to normal ranges and, in parallel, rescues
Ca2+ signaling in NPC1I1061T fibroblasts. Collectively, these data
suggest that lysosomal NPC1 protein is a key gatekeeper in not
only cholesterol metabolism but also Ca2+ homeostasis and
synaptic architecture.
SREBP-dependent changes in PSEN1 regulate Ca2+ homeostasis
SREBPs are a family of transcription factors often described as
master regulators of lipid homeostasis through their ability to
acutely sense the concentration of ER cholesterol and maintain
its concentration within a precise physiological range (Brown
and Goldstein, 1997). SREBPs not only control cholesterol syn-
thesis with remarkable “switch-like” precision (Radhakrishnan
et al., 2008) but also are implicated in the direct (via the sterol
response elementmotif) or indirect regulation of∼1,500 protein-
coding genes with a variety of functions (Rome et al., 2008). We
have provided novel evidence to suggest that Ca2+ handling
proteins with important roles in Ca2+ homeostasis and SOCE can
have their protein expressions altered via SREBP. Of note, we
find that PSEN1 (discussed below), STIM1, and ORAI1 can have
their mRNA and protein abundances increased by SREBP in
circumstances of reduced NPC1 cholesterol egress (such as NPC
disease) to decrease ER Ca2+ concentrations and subsequently
increase SOCE.
PSEN1 is an interesting protein at the center of this SREBP-
dependent regulation of Ca2+ homeostasis in NPC1 disease. Our
evidence for the involvement of PSEN1 is robust: (1) PSEN1 is
elevated in NPC1I1061T patient cells, (2) PSEN1 siRNA is sufficient
to abrogate the changes in ER luminal Ca2+ and SOCE, (3) over-
expression of the holoprotein recapitulates NPC1 ER Ca2+ loss,
and (4) PSEN1−/− cells do not exhibit UA-dependent changes in
Ca2+ signaling. PSEN1 has been proposed to act as low-
conductance, passive ER Ca2+ leak channel, with mutations in
the PSEN1 protein leading to disruption or abolishment of ER
Ca2+ leak activity in familial Alzheimer’s disease (Tu et al., 2006;
Nelson et al., 2007, 2011). However, such a role for PSEN1 or
PSEN2 is controversial (Shilling et al., 2012) and has been
challenged by groups who determined that PSEN1 can interact
with inositol triphosphate receptors (IP3R) to prolong IP3R
opening and Ca2+ leak permeability (Cheung et al., 2008;
Shilling et al., 2014), while others have reported that mutant
PSEN1 increases the expression and recruitment of ryanodine
receptors to regulate the IP3R Ca2+ signaling in primary
neurons (Stutzmann et al., 2006). Our PSEN1 data fit a simple
model in which its increased expression leads to an enhanced
intrinsic ER Ca2+ leak to decrease ER Ca2+ concentrations to a
level (∼170 µM) that facilitates continuous interactions be-
tween STIM1 and ORAI, leading to constitutive Ca2+ entry
(Luik et al., 2008). Thus, instead of the Ca2+ entering the cy-
toplasm through ORAI1 channels, being pumped via SERCA
back into the ER lumen to terminate SOCE, it simply leaks out
to perpetuate a feedforward Ca2+ signaling loop. Despite this
evidence, further experiments are required to fundamentally
address the relationship between PSEN1 and other Ca2+ re-
lease channels in NPC1 disease.
Further underscoring the importance of PSEN1, we demon-
strate that knocking it down reduces cholesterol accumulation
in NPC1I1061T disease fibroblasts. This is in line with other groups
who demonstrate that targeting ER proteins, including SERCA
(Lloyd-Evans et al., 2008), ryanodine receptors (Yu et al., 2012),
or calreticulin (Wang et al., 2017), can clear metabolites from
cells with lipid storage deficiencies. Mechanistically, elevations
in ER Ca2+ levels likely remodel the protein-folding environment
in the ER to increase steady-state levels of NPC1 (Yu et al., 2012).
These data underscore the need for further work detailing the
mechanistic underpinnings and timeline of progression of this
Ca2+ phenotype, as it may be therapeutically beneficial for NPC
patients and others with lysosomal storage disorders.
Consequences of decreased ER Ca2+ and enhanced SOCE for
cell signaling and neurodegeneration
Given the role of Ca2+ as a ubiquitous secondmessenger, it is clear
that deviant elevations in intracellular Ca2+ can have detrimental
effects on cell health and survival. This is highlighted by the Ca2+
hypothesis for neurodegeneration, which postulates that disrup-
tion of intracellular Ca2+ signaling is pivotal for the molecular
mechanisms underlying neuronal degeneration (Biessels and
Gispen, 1996; Berridge, 2010; Alzheimer’s Association Calcium
Hypothesis Workgroup, 2017). Thus, inhibition of lysosomal
cholesterol efflux leading to activation of SREBP and downstream
changes in local Ca2+ gradients could very well be toxic to cells.
Underscoring this idea, UA-treated hippocampal neurons and
NPC1I1061T brain slices exhibit reductions in neuron spine density
that are time locked with dysfunctional Ca2+ signaling. Given that
Ca2+ is a crucial regulator of dendritic spine plasticity (Higley and
Sabatini, 2012), and there is a strong correlation between reduc-
tion/elimination of spines and age-dependent memory loss
and neurodegeneration (Walsh and Selkoe, 2004; Knobloch
and Mansuy, 2008; Marcello et al., 2012; Yu and Lu, 2012;
Bezprozvanny and Hiesinger, 2013), it follows that mechanisms
controlling spine Ca2+ homeostasis may be important for pro-
gression of neurodegenerative conditions. In fact, there is growing
evidence linking dysfunction of ER Ca2+ homeostasis and/or SOCE
to alterations in dendritic spine density across several neurode-
generative disorders (Sugawara et al., 2013; Sun et al., 2014; Zhang
et al., 2015, 2016; Herms and Dorostkar, 2016; Tong et al., 2016;
Wu et al., 2016; Korkotian et al., 2017). Our data provide a testable
framework to determine if altered ER Ca2+ signaling and synapse
loss and/or dendritic regression contributes to cognitive issues in
animals with NPC disease.
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In conclusion, we report a molecular pathway that links
NPC1-mediated efflux of cholesterol from lysosomes to tuning of
cytoplasmic Ca2+, ER Ca2+, and SOCE. Connecting cholesterol
efflux to changes in Ca2+ is the SREBP pathway, which is active
after inhibition or disease mutations in the NPC1 protein, to
differentially regulate key Ca2+ signaling proteins, including
PSEN1.When active, this pathway increases dendritic spine Ca2+
concentrations to modulate synaptic plasticity. This works fur-
thers our understanding of lysosome signaling networks and
offers a putative contributory mechanism to the neuropathology
of NPC disease and potentially other cholesterol-linked neuro-
degenerative disorders.
Materials and methods
Cell culture
Fibroblast cell lines derived from an apparently healthy male
(GM05659) and a male patient with the NPC1I1061T mutation
(GM18453) were purchased from Coriell Institute. Additional
fibroblast cell lines derived from patients, NPC1I1061T, I1061T and
NPC1I1061T, P1007A, were generously provided by Dr. Forbes D.
Porter (National Institutes of Health, Bethesda, MD). Fibroblasts
were cultured in MEM supplemented with 2 mM L-glutamine,
15% non–heat-inactivated FBS, and 0.2% penicillin/streptomy-
cin. Cells were passaged twice weekly and incubated in 5% CO2
at 37°C. PSEN+/+ (WT) and PSEN1/PSEN2 double-knockout
(PSEN−/−) MEFs were a generous gift from Drs. David Kang,
Angels Almenar, and Lawrence S.B. Goldstein (University of
California, San Diego, San Diego, CA). WT, NPC1−/−, and SCAP−/−
CHO cells were kindly provided by Daniel Ory (Washington
University, St. Louis, MO). MEFs, CHO cells, and tsA201 cells
were cultured in DMEM supplemented with 10% FBS and 0.2%
penicillin/streptomycin. Hippocampal Neurons were isolated
from rats at gestation day 18. Neurons were cultured in Neu-
robasal (21103-049; Gibco) supplemented with B27 (17504-044;
Gibco), Glutamax (35050-061; Gibco), 5% FBS, and 0.2% peni-
cillin/streptomycin. On DIV 7, cytosine-D-arabinofuranoside
(251010; Millipore) at 1:1,000 was added to neuronal cultures to
inhibit astrocyte growth.
Murine model of NPC1 disease
C57BL/6 WT mice and NPC1I1061T knock-in mice (Praggastis
et al., 2015) were kindly provided by Daniel Ory. The animal
handling protocol was approved by the University of California
Institutional Animal Care and Use Committee. Mice were fed
standard chow and water ad libitum and housed in a vivarium
with controlled conditions. Genotyping of NPC1I1061T mice was
performed by isolating DNA from mice tails and using PCR with
the following primers: NPC1 forward, 59-TGATCTGCACACTTG
GAACCGAG-39; and NPC1 reverse, 59-CACTGCCTTGAGCAGCAT
CTCAG-39. Genotype was identified by a 200-bp fragment for
WT and a 234-bp fragment for NPC1I1061T. Animals used in the
studywere from symptomatic time points (postnatal day 85–95).
Filipin staining and AiryScan superresolution imaging
Cells were washed with PBS and fixed in 3% PFA and 0.1%
glutaraldehyde for 10 min at 21°C. Cells were then incubated
with sodium borohydrate (10 mM) for 5 min and subsequently
stained with filipin (3 mg/ml in PBS) for 2 h at room tempera-
ture or overnight at 4°C. Cells were excited using a 405-nm LED
and light collected using a Plan-Apochromat 63×/1.40 oil-
immersion lens and a Zeiss 880 Airyscan microscope. Images
were acquired in PBS solution at room temperature (21–23°C)
using Zen software.
Ca2+ imaging
Cells were incubated for 30 min in 5 µM Fluo-4 in 2 mM Ca2+
Ringer’s solution (160 mM NaCl, 2 mM CaCl2, 1 mM MgCl2,
2.5 mM KCl, 10 mM Hepes, and 8 mM glucose) with 0.1%
pluronic acid to permeabilize cells. Cells were then moved to a
Fluo-4–free Ringer’s solution to deesterify for 30 min. Following
deesterification, Fluo-4–loaded cells were excited with a 488-nm
laser and the resulting fluorescence monitored using an inverted
microscope with a Plan-Apochromat 63×/1.40 oil objective,
connected to an Andor W1 spinning-disk confocal with a Pho-
tometrics Prime 95B camera. Images were acquired every 2–5 s
in Ringer’s solution at room temperature (21–23°C) using Mi-
cromanager software. Hippocampal neurons were imaged at
DIV 21; Ca2+ measurement regions of interest in neurons were
restricted to dendritic spines. SOCE was induced by initially
perfusing cells in 2 mM Ca2+ solution; cells were then perfused
in Ca2+-free solution (160 mM NaCl, 2 mM EGTA, 1 mM MgCl2,
2.5 mM KCl, 10 mMHepes, and 8 mM glucose), followed by 500
nM TG in Ca2+-free solution. After 5 min of TG incubation, cells
were exposed to 2 mM Ca2+ solution to measure resulting SOCE.
Resting Fluo-4 intensities were measured by normalizing to the
minimum fluorescence in an ionomycin-containing Ca2+-free
solution. Ca2+ dyes and the D1-ER FRET probe were calibrated
using standard empirical calculations as previously described
(Palmer et al., 2004).
Transfections, plasmids, and siRNA
The following cDNA plasmids were used in this study (in order
of appearance): pGP-CMV-GCaMP6s-CAAX (plasmid 52228;
Addgene), mCherry-STIM1 (kind gift from Richard Lewis,
Stanford University, Stanford, CA), ORAI1-GFP (Dickson et al.,
2012), D1-ER-CAM (Palmer et al., 2004), PSEN1 and PSEN1-
D257A (kind gifts from Ilya Bezprozvanny, University of Texas
Southwestern, Dallas, TX), GCaMP3-ML1 (kind gift from Haox-
ing Xu, University of Michigan, Ann Arbor, MI; Shen et al.,
2012), and lyso-pHoenix (plasmid 70112; Rost et al., 2015;
Addgene). The DsiRNA Duplex targeting PSEN1 was from Inte-
grated DNA Technologies. Transfections of cDNA or DsiRNA
were prepared using Lipofectamine LTX (15338-030; In-
vitrogen) and Lipofectamine RNAiMAX (13778-030; Invitrogen),
respectively, in Opti-MEM (31985-062; Gibco). Transfections
were incubated overnight for 24 h before imaging, unless
otherwise noted.
Ground state depletion superresolution imaging
Fibroblasts were fixed in 4% PFA for 15 min followed by per-
meabilization with 0.1% Triton X-100 for 10 min, blocked with
4% FBS for 1 h at 21°C, and stained with rabbit polyclonal anti-
ORAI1 (ACC-060, 1:200; Alomone) or rabbit polyclonal anti-STIM1
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(HPA012123, 1:1,000; Sigma-Aldrich) overnight at 4°C. Fi-
broblasts were then washed and incubated for 1 h in Donkey
Anti-Rabbit Alexa Fluor 647 (1:1,000; Invitrogen) secondary
antibody. Superresolution imaging was performed as previ-
ously described (Dixon et al., 2017) using a Leica GSD super-
resolution microscope. Representative images are displayed
at 20-nm pixel size; particle analysis was conducted using 10-
nm pixel size.
Protein extraction and Western blot
Protein from cultured cells was harvested using RIPA Buffer
(89900; Thermo Fisher Scientific) with complete, Mini,
EDTA-free protease inhibitor (11836170001; Roche) for
25 min at 4°C. Samples were sonicated, and postnuclear su-
pernatant was isolated by centrifugation for 25 min at
13,200 g at 4°C. Concentration of protein lysate was quanti-
fied using Pierce BCA protein assay kit (23225; Thermo Fisher
Scientific). Protein samples were resolved in 4–12% Bis-Tris
gels under reducing conditions. Proteins were transferred
from gels onto 0.2-µm polyvinylidene difluoride membranes
(#LC2000; Life Technologies) using a Mini-Bolt system
(A25977; Thermo Fisher Scientific). using rabbit monoclonal
anti-NPC1 (ab134113, 1:2,000; Abcam), rabbit polyclonal
anti-ORAI1 (ACC-060, 1:200; Alomone), rabbit polyclonal
anti-STIM1 (HPA012123, 1:1,000; Sigma-Aldrich), rabbit pol-
yclonal anti-STIM2 (ACC-064, 1:200; Alomone), mouse
monoclonal anti-SERCA2 (ab2861, 1;1,000; Abcam), mouse
monoclonal β-actin (MA1-91399 1:10,000; Abcam) Calreticu-
lin (PA3-900; Thermo Fisher Scientific), mouse monoclonal
anti-SREBP1 (MA5-11685; Invitrogen), rat monoclonal anti-
PSEN1 N-terminal fragment (MAB1563; MilliporeSigma),
and mouse monoclonal anti-PSEN1 C-terminal fragment
(MAB5232; MilliporeSigma). Blot bands were detected using
fluorescent secondary antibodies goat anti-rabbit 680RD (P/
N 926-68071, 1:10,000; LI-COR), goat anti-Mouse 800CW (P/
N 925-32210, 1:10,000; LI-COR), and goat anti-rat 680 (A-
21096, 1:10,000; Invitrogen). ImageJ was used to calculate the
fluorescent density of each band. Abundance of proteins were
normalized to β-actin; treatment group protein expression
was normalized to protein abundance from the appropriate
controls.
mRNA extraction and quantitative real-time PCR
mRNA was isolated from fibroblasts using RNeasy Plus Mini Kit
(74134; Qiagen). cDNA was synthesized from 1 µg of total RNA
using AffinityScript cDNA Synthesis Kit (600559; Agilent).
Quantitative real-time PCRwas performed using PowerUp SYBR
Green Master Mix (A25741; Applied Biosystems). C-terminal
fragment values were normalized to β-actin. The following
primer sequences were used: β-actin forward, 59-AGAGCTACG
AGCTGCCTGAC-39; β-actin reverse, 59-AGCACTGTGTTGGCG
TACAG-39; STIM1 forward, 59-AGTCACAGTGAGAAGGCGAC-39;
STIM1 reverse, 59-CAATTCGCGAAAACTCTGCTG-39; ORAI1 for-
ward, 59-GACTGGATCGGCCAGAGTTAC-39; ORAI1 reverse, 59-
GTCCGGCTGGAGGCTTTAAG-39; PSEN1 forward, 59-GAAGCT
CAAAGGAGAGTATCCA-39; PSEN1 reverse, 59-CCCTAGATGACT
GTCCCTCT-39; PSEN1 forward, 59-GAAGCGTATACCTAATCT
GGGA-39; and PSEN1 reverse, 59-CACAGAAAACAAAGCCTCTTG
AG-39.
Immunocytochemistry of dendritic spines
Cultured hippocampal neurons were initially washed with
PBS and fixed at DIV 21 in 4% PFA for 15 min followed by
permeabilization with 0.1% Triton X-100 for 10 min. The
neurons were then blocked with 4% FBS for 1 h at 21°C
and stained with rabbit polyclonal anti-MAP-2 (AB5622-I,
1:1,000; MilliporeSigma) and mouse monoclonal anti-PSD-95
(75-028, 1:500; Neuromab) overnight at 4°C. Neurons were
then washed and incubated 1 h in goat anti-rabbit Alexa Fluor
647 (1:1,000; Invitrogen) and Goat anti-mouse Alexa Fluor
555 (1:1,000; Invitrogen) secondary antibodies and subse-
quently imaged in PBS using a Plan-Apochromat 63×/1.40 oil
DIC M27 objective (superresolution; 880 Airyscan; Zeiss).
Images were acquired at room temperature (21–23°C) using
Zen software.
Golgi staining of cerebellar slices
Cerebellums were isolated from paired age- and sex-matched
WT and NPC1I10161T mice between 70 and 90 d old. Golgi stain-
ing was performed using an FD Rapid GolgiStain Kit (PK401A;
FD NeuroTechnologies). Slices were imaged with transmitted
light using a 63×/1.40 oil objective connected to an Andor
W1 spinning-disk confocal coupled to a Photometrics Prime 95B
camera; only Purkinje neurons were assessed for imaging. Im-
ageJ was used to develop representative binary skeletons for
quantitative analysis of dendritic spine branching.
Reagents
UA (Sigma-Aldrich) was dissolved in DMSO and used at a final
concentration of 1 µM. AnCoA4was dissolved in DMSO and used
at a final concentration of 50 µM. PF-429242 (Tocris) was dis-
solved in DMSO and used at a final concentration of 500 nM. TG
(Sigma-Aldrich) was dissolved in DMSO and used at a final
concentration of 500 nM. Ionomycin (Sigma-Aldrich) was dis-
solved in DMSO and used at a final concentration of 2.5 to 5 µM.
ML-SA1 (Sigma-Aldrich) was dissolved in DMSO and used at a
final concentration of 10 µM.
Data analysis
Microsoft Excel, GraphPad Prism, and IGOR PRO were used to
analyze all data. ImageJ was used to process and analyze images.
Parametric Student’s t tests were conducted to determine
significance; P values <0.05 were considered as statistically
significant. P values and number of cells are detailed in each
figure or figure legend.
Online supplemental material
Fig. S1 shows impaired cholesterol distribution, ER Ca2+, and
SOCE across multiple models of NPC1 disease. Fig. S2 shows
enhanced ICRAC current and STIM1/ORAI1 activation in NPC1
disease fibroblasts. Fig. S3 demonstrates the involvement of
PSEN1 as a regulator of ER Ca2+ levels in healthy and NPC1
disease cells. Fig. S4 shows the involvement of the SREBP
pathway in mediating transcriptional and functional changes in
Tiscione et al. Journal of Cell Biology 4154
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Ca2+ signaling in NPC1 disease. Fig. S5 shows the effect of SREBP
inhibitor PF-429242 in appropriate control cells.
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